How Neoadjuvant Therapy Changes the Tumor Environment in Esophageal Cancer
Author Information
Author(s): Qiu Zhengzhou, Li Zhao, Liu Xingfei, Zhang Ruilin, Li Yongxuan, Gao Chenggen, Mao Xiaoling, Bao Yin, Zhang Mingyue, Guo Changying
Primary Institution: Jiangxi Medical College, Nanchang University, Nanchang, China
Hypothesis
Exploring changes in the tumor microenvironment can help identify reliable biomarkers for patient responsiveness to immunotherapy.
Conclusion
Neoadjuvant chemotherapy combined with immunotherapy significantly alters the tumor microenvironment and improves patient outcomes in esophageal squamous cell carcinoma.
Supporting Evidence
- Neoadjuvant immunotherapy improves pathological response rates and extends patient survival.
- Patients with higher CD8+ T cell infiltration after treatment have better outcomes.
- Existing biomarkers have shown limited sensitivity in predicting treatment outcomes.
Takeaway
This study looks at how treatment changes the environment around esophageal cancer cells, which can help doctors find better ways to predict how well patients will respond to therapy.
Methodology
The study utilized single-cell RNA sequencing to analyze samples from patients with esophageal squamous cell carcinoma undergoing neoadjuvant therapy.
Limitations
The study is limited by the small sample size and the complexity of the tumor microenvironment.
Participant Demographics
Patients with esophageal squamous cell carcinoma undergoing neoadjuvant therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website